Hormone Receptor Positive Tumor Recruiting Phase 2 Trials for Durvalumab (DB11714)

IndicationStatusPhase
DBCOND0075370 (Hormone Receptor Positive Tumor)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03874325Aromatase Inhibitor and Durvalumab in Postmenopausal Breast CancerTreatment